pharma news today glp-1 obesity A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Weight-loss therapy set to push

Popular weight-loss medications may also affect aspects of sexual health, recent research has shown

Underlying Medical Conditions Thyroid disorders, hormonal imbalances, chronic inflammation, and sleep apnea can reduce the bodys responsiveness to weight loss interventions, even when using GLP-1 drugs

For the general adult population, the recommended daily allowance for protein is 0.8 g per kg of body weight per day [152]

Alcohol consumption, particularly frequent binge drinking, impairs metabolic function and increases inflammation, both of which reduce GLP-1 medication effectiveness

Tirzepatide (Mounjaro, Zepbound) Unopened: Refrigerate at 36F46F (2C8C) until first use

brand Wegovy and oral Rybelsus remain Novo Nordisk products, while Eli Lilly's tirzepatide products Mounjaro and Zepbound are not affected by the semaglutide generic decisions